Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Getty Images
The Food and Drug Administration announced Monday that it has approved a prescription cannabis-based medicine — a purified form of the drug cannabidiol, which doesn't produce a high — to treat severe forms of epilepsy in patients two and older.
Why it matters: This is the first FDA-approved cannabis-based drug to hit the market. Meanwhile, commissioner Dr. Scott Gottlieb cautioned in a statement: "This is an important medical advance. But it’s also important to note that this is not an approval of marijuana or all of its components."